Russian Pharmalicensing Group - News

+7 495 640 5275


Keeping clients informed is one of our major priorities. Be the first to get updates on regulatory issues and news.

The Russian Supreme Court Sided With Biotec in a Dispute With Teva

2 December 2015

1st December 2015 Chamber for Commercial Disputes of the Supreme Court of Russian Federation delivered a judgement in favor of ZAO Biotec, a member of the group of companies Biotec, to recover of damages from the Israeli company Teva Pharmaceutical industries Ltd. in the amount of 408 375 000 rubles.

The Court agreed with the arguments of Biotec Company that the Israeli company violated the terms of the agreement signed in 2010, unlawfully denying the Russian partner in the supply of pharmaceutical preparation Copaxone-Teva produced by Teva company. Earlier, the Federal Antimonopoly Service of Russia, having considered complaints of Biotec company, also recognized the Israeli company responsible for the violation of Russian Antimonopoly Legislation due to failures in the supply of the drug.

Pharmaceutical preparation Copaxone-Teva is included in the state List of Vital and Essential Drugs and is used to treat multiple sclerosis.

back to headlines